Pathwork Diagnostics logo

Pathwork Diagnostics

Pioneering molecular diagnostics for oncology with the first FDA-cleared microarray-based gene expression test to identify challenging tumors.

est. 2002

VS
Sola Diagnostics GmbH logo

Sola Diagnostics GmbH

The WID®-easy Test - Now also available in Switzerland 🇨🇭 👉 Unnecessary hysteroscopy and curettage can be avoided

2 employees · est. 2020 · Innsbruck, Austria

Pathwork Diagnostics is the older company (2002 vs 2020).

Side-by-Side Comparison

Pathwork Diagnostics Sola Diagnostics GmbH
Founded
2002 older 2020
Headquarters
Not tracked yet Innsbruck, Austria
Employees
Not tracked yet 2
Industry
Biotechnology, Health Care Biotechnology, Health Care
Funding Stage
Series Unknown Seed
Total Funding
Not tracked yet $2.39M
Funding Rounds
Not tracked yet 5
Services
Not tracked yet Developing and providing epigenetic diagnostic tests for gynecological cancer detection
Target Customers
Not tracked yet Patients, healthcare providers, and laboratories
Taxonomy
Molecular Diagnostics, Oncology, Gene Expression Test, FDA Clearance, Microarray-based Test, Tissue Of Origin Test, Cancer, Metastatic Cancer, Tumor Identification, Redwood City, California, Innovation, Diagnostic Technology Women's Health Diagnostics, Epigenetic Testing, Gynecological Diagnostics, DNA Methylation, PCR-based Analysis, Clinical Validation, First-line Diagnostic, Non-invasive Testing, Cancer Detection, Startup Expansion, Private Equity Investment
Website
pathworkdx.com sola-diagnostics.com
Pathwork Diagnostics logo

About Pathwork Diagnostics

Pathwork Diagnostics is a biotechnology company based in Redwood City, California, founded in 2002. The company specializes in pioneering molecular diagnostics for oncology, particularly focusing on developing advanced tests for identifying challenging tumors. Notably, Pathwork Diagnostics achieved...

Sola Diagnostics GmbH logo

About Sola Diagnostics GmbH

Sola Diagnostics GmbH is a biotechnology and healthcare startup which is the home of the WID®-Test. Founded in 2020 and headquartered in Austria, the company has recently secured a €400.00K Seed Round investment from FPS-Holding on 20 February 2025. Their slogan "The WID®-easy Test - Now also availa...

We will tell you when either one moves

BounceWatch watches Pathwork Diagnostics and Sola Diagnostics GmbH for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Pathwork Diagnostics and Sola Diagnostics GmbH — by email.

Frequently Asked Questions

Pathwork Diagnostics — Pioneering molecular diagnostics for oncology with the first FDA-cleared microarray-based gene expression test to identify challenging tumors.. Sola Diagnostics GmbH — The WID®-easy Test - Now also available in Switzerland 🇨🇭 👉 Unnecessary hysteroscopy and curettage can be avoided. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Pathwork Diagnostics has raised undisclosed funding while Sola Diagnostics GmbH has raised $2.39M.
Pathwork Diagnostics and Sola Diagnostics GmbH operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Pathwork Diagnostics with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Pathwork Diagnostics on 12 Sep 2024, and Sola Diagnostics GmbH on 13 Apr 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy